Evaluating the Clinical Outcomes of Empagliflozin in Heart Failure Patients With Preserved Ejection Fraction: A Systematic Review
Abstract
Heart failure with preserved ejection fraction (HFpEF) represents a significant clinical challenge due to its complex pathophysiology and limited therapeutic options. This systematic review evaluates the efficacy and safety of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in patients with HFpEF. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we analyzed 11 studies, predominantly from the EMPEROR-Preserved trial and its sub-analyses, investigating empagliflozin in HFpEF patients. Our findings consistently demonstrate that empagliflozin significantly reduces heart failure hospitalizations (HR 0.71, 95% CI 0.60-0.83) across diverse patient populations. This benefit was observed regardless of sex, age, diabetes status, blood pressure, and frailty levels, although effects were attenuated in patients with higher ejection fractions and in severely frail individuals. Notably, empagliflozin did not significantly reduce cardiovascular mortality, although a non-significant trend toward benefit was observed in certain subgroups. Additional benefits included slowed decline in renal function and improved quality of life measures. The safety profile was favorable across all studies, with good tolerability even in elderly and frail populations. These findings position empagliflozin as a valuable addition to the limited therapeutic armamentarium for HFpEF, particularly for reducing hospitalizations and improving…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.